10 October 2012
Update | Sector: Capital Goods
Crompton Greaves
BSE SENSEX
S&P CNX
18,709
5,676
CMP: INR134
TP: INR163
Upgrade to Buy
One CG: Whole > Sum of Parts
Overseas turnaround a key trigger; risk-reward favorable
Bloomberg
CRG IN
Equity Shares (m)
641.5
52-Week Range (INR) 175/102
1,6,12 Rel. Perf. (%) 16/-11/-25
M.Cap. (INR b)
86.0
M.Cap. (USD b)
1.6
Valuation summary (INR b)
Y/E March
2012 2013E 2014E
Net Sales
112.5 131.3 145.9
EBITDA
8.0 10.9 13.8
NP
3.7
6.0
8.0
EPS(INR)
5.7
9.3 12.6
EPS Gr. (%)
-60.0 62.2 36.0
BV/Sh (INR) 56.3 63.0 71.4
P/E (x)
23.4 14.4 10.6
P/BV (x)
2.4
2.1
1.9
EV/EBITDA (x) 13.3
8.3
6.3
EV/ Sales (x)
0.9
0.7
0.6
RoE (%)
10.7 15.6 18.7
RoCE (%)
9.6 13.0 15.0
* Consolidated
For Crompton Greaves (CG), the attempt now is to ensure that 'the value of the whole
is substantially more than the sum of the parts' and make a full transformation to a
global corporation. We believe this journey provides several levers to boost revenues.
Expect Hungary, Canada and USA (40% of international subsidiary revenues) to turn
profitable by mid-FY13, leading to turnaround in overseas operations.
We model 47% consolidated EPS CAGR over FY12-14 driven by 14% revenue CAGR and
230bp margin expansion. The key risk is that macro environment remains challenging.
We arrive at price target of INR163, based on P/E of 12x FY14E for standalone business
and EV/EBITDA of 8x FY14E for overseas business. Upgrade to Buy.
Synergy-led revenue growth; breaking 'silo structures'
Over the years, CG has evolved from being largely an "India player" to an "Indian
corporation with an international business". The attempt now is to make a full
transformation to a global corporation. This journey provides several levers to
boost revenues:
Organizational restructuring across geographies / product segments to break
'silo' structures for integrated product offerings
Internationalization and integration of industrial business, to possibly double
revenues over the medium-term
New factories / new products in new geographies to contribute meaningfully
Recent acquisitions like Emotron / ZIV have targets to nearly treble revenues
in 3 years given synergy benefits,
Rejuvenation of consumer business portfolio, and
Steady growth and dominant positioning (market share 25-50%) in niche areas
of renewable segments, etc.
Shareholding pattern (%)
As on
Jun-12 Mar-12 Jun-11
Promoter
41.7
41.7
42.8
Dom. Inst 21.7
20.3
18.3
Foreign
21.0
20.3
23.2
Others
15.6
17.7
15.7
Potential turnaround in international operations in FY13
In the overseas markets, performance in key geographies like Belgium (36% of
revenues), USA (24%), Hungary (9%) and Canada (6%) were impacted in FY12
given pricing pressures and region / factory specific issues. We believe USA,
Hungary and Canada could become profitable during FY13. The recovery will also
be aided by benefits of improve d raw material sourcing and decline in commodity
prices. We expect international subsidiaries to report FY13/14 EPS of INR0.5/1.7,
from loss of INR2.1/sh in FY12.
Stock performance (1 year)
Expect Consolidated EPS CAGR of 47% over FY12-14; Upgrade to Buy
We model 47% consolidated EPS CAGR over FY12-14 driven by 14% revenue CAGR
and 230bp margin expansion. The key risk is that macro environment remains
challenging. Also, reported financials over past five quarters have been
disappointing and stock price have reacted sharply, post results. We arrive at
price target of INR163, based on P/E of 12x FY14E for standalone business and EV/
EBIDTA of 8x FY14E for overseas business.
Upgrade to Buy.
1
Investors are advised to refer
through disclosures made at the end
of the Research Report.
Satyam Agarwal
(AgarwalS@MotilalOswal.com); +91 22 3982 5410
Deepak Narnolia
(Deepak.Narnolia@MotilalOswal.com); +91 22 3982 5126